Get the Stockscreener App
1.54
6.10%
-0.10
After Hours:
1.53
-0.01
-0.65%
Pacific Biosciences Of California Inc stock is traded at $1.54, with a volume of 13.04M.
It is down -6.10% in the last 24 hours and down -9.41% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.64
Open:
$1.69
24h Volume:
13.04M
Relative Volume:
1.19
Market Cap:
$421.75M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.0267
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-16.76%
1M Performance:
-9.41%
6M Performance:
-0.32%
1Y Performance:
-69.69%
1-Day Range:
$1.53
$1.69
1-Week Range:
$1.53
$2.01
52-Week Range:
$1.16
$6.09
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.54 | 421.75M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Revenue Downgrade: Here's What Analysts Forecast For Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14% - Yahoo Finance
Analysts Issue Forecasts for PACB FY2025 Earnings - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Michele Farmer Sells 24,349 Shares - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
A chromosome-scale reference assembly of Vigna radiata enables delineation of centromeres and telomeres - Nature.com
How HiFi sequencing is making a difference for rare disease research at Children’s Mercy - Pacific Biosciences
Traders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB) - MarketBeat
Pacific Biosciences Officer Sells Over 259K Shares - TradingView
PacBio to Present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 - Nasdaq
The Goldman Sachs Group Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50 - MarketBeat
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - Quantisnow
Life sciences stocks fall on NIH funding concerns - MSN
Where Pacific Biosciences Stands With Analysts - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownTime to Sell? - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Announces Quarterly Earnings Results - MarketBeat
StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks - Genetic Engineering & Biotechnology News
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Stephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday - MarketBeat
PacBio's Strategic Talent Move: 700K Share Package Signals Major Executive Addition - StockTitan
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
PacBio Grants Equity Incentive Award to New Employee - GlobeNewswire Inc.
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Meets Estimates - MarketBeat
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga India
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall - Yahoo Finance
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating - Marketscreener.com
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Pacific Biosciences: Q4 Earnings Snapshot - Huron Daily Tribune
PacBio outlines 2025 revenue guidance of $155M-$170M amid new product launches - MSN
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates - MSN
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics - MSN
PacBio (NASDAQ:PACB) Misses Q4 Sales Targets - Yahoo Finance
Pacific Biosciences Of California, Inc. Q4 Earnings Summary - Nasdaq
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results - TradingView
PacBio Reports Q4 2024 Financial Results Highlighting Revenue Decline and Strategic Developments - Nasdaq
Pacific Biosciences of California, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
PacBio Earnings: $154M Debt Restructuring Win Masks 33% Revenue Decline - StockTitan
Pacific Biosciences Of California Q4 24 Earnings Conference Call At 4:30 PM ET - Nasdaq
Trump’s Cuts to Medical Research Are Hurting These Stocks - Barron's
How HiFi sequencing lays the groundwork for accelerating rare disease diagnostics in the clinic - Pacific Biosciences
PacBio (PACB) Q4 Earnings Report Preview: What To Look For By Stock Story - Investing.com Canada
PacBio (PACB) Q4 Earnings Report Preview: What To Look For - Yahoo Finance
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Feb 18 '25 |
Sale |
1.88 |
100,773 |
189,252 |
1,496,681 |
| HENRY CHRISTIAN O | See Remarks |
Feb 18 '25 |
Sale |
1.88 |
259,909 |
488,109 |
2,237,854 |
1.16%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):